Q2 Earnings Estimate for CapsoVision Issued By Roth Capital

Key Points

• Roth Capital has projected CapsoVision's Q2 2025 earnings per share at ($0.11) and maintains a "Strong-Buy" rating with a price target of $6.00.
• Estimates from Roth Capital indicate that CapsoVision will continue to post negative earnings in upcoming quarters, with expected FY2025 earnings of ($0.49) EPS.
• CapsoVision's stock is currently trading at $4.54, with a one-year price range between $3.49 and $5.72.

CapsoVision, Inc. (NASDAQ:CV - Free Report) - Stock analysts at Roth Capital issued their Q2 2025 earnings per share (EPS) estimates for CapsoVision in a report issued on Monday, July 28th. Roth Capital analyst J. Wittes expects that the company will earn ($0.11) per share for the quarter. Roth Capital currently has a "Buy" rating and a $6.00 target price on the stock. Roth Capital also issued estimates for CapsoVision's Q3 2025 earnings at ($0.12) EPS, Q4 2025 earnings at ($0.13) EPS, FY2025 earnings at ($0.49) EPS, Q1 2026 earnings at ($0.06) EPS, Q2 2026 earnings at ($0.07) EPS, Q3 2026 earnings at ($0.03) EPS, Q4 2026 earnings at ($0.04) EPS, FY2026 earnings at ($0.20) EPS, FY2027 earnings at ($0.01) EPS, FY2028 earnings at $0.35 EPS and FY2029 earnings at $0.58 EPS.

Several other research firms have also commented on CV. Benchmark assumed coverage on CapsoVision in a report on Monday. They set a "speculative buy" rating and a $5.00 target price for the company. Wall Street Zen upgraded CapsoVision to a "hold" rating in a research report on Sunday, July 13th.

CapsoVision Trading Up 1.0%

Shares of NASDAQ:CV traded up $0.04 during trading on Wednesday, hitting $3.91. The company's stock had a trading volume of 50,843 shares, compared to its average volume of 124,694. CapsoVision has a fifty-two week low of $3.49 and a fifty-two week high of $5.72.

CapsoVision Company Profile

We are a commercial-stage medical technology company that develops advanced imaging and artificial intelligence (“AI”) technologies that are deployed in our capsule endoscopy solutions to identify abnormalities of the gastrointestinal (“GI”) tract for diagnostic and screening purposes. We developed our first capsule endoscope system, currently comprising the CapsoCam Plus single-usecapsule and the CapsoCloud and CapsoView software, to panoramically visualize the small-bowel mucosa to investigate abnormalities such as obscure GI bleeding and Crohn's disease.